Clinical Trial Update: A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Onartuzumab (MetMAb) with the mFOLFOX6 regimen in metastatic HER2-negative gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Onartuzumab (MetMAb) (onartuzumab)
• mFOLFOX6 regimen

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED